Two new indications for rituximab.
Kahl
Brad S
BS
Lymphoma Service, University of Wisconsin School of Medicine, Hematology Disease-Oriented Working Group, Paul P. Carbone Comprehensive Cancer Center, Madison, WI, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D000069283:Rituximab; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab